logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Biocon Biologics To Acquire Viatris' Biosimilars Assets For Up To Usd 3.335 Billion In Stock And Cash

Feb 28, 2022•almost 4 years ago

Acquiring Company

Biocon Biologics

Acquired Company

Biosimilars Assets

BengaluruBiopharmaBiotechnology

Description

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. (BSE code: 532523) (NSE: BIOCON), has entered into a definitive agreement with its partner Viatris Inc. (NASDAQ: VTRS). Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris' biosimilars business to create a unique fully integrated global biosimilars enterprise. The revenues of this acquired business are estimated to be USD 1 billion next year. Viatris will receive consideration of up to USD 3.335 billion in cash and stock.

Company Information

Company

Biocon Biologics

Location

Bengaluru, Karnataka, India

About

We are a global biopharmaceutical company with the belief that everyone, everywhere deserves access to affordable quality medicines. Kiran Mazumdar-Shaw appointed as member of the Court of Regents at the Royal College of Surgeons of Edinburgh

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed